AMG 330 Appears Safe, Tolerable in Relapsed/Refractory Acute Myeloid Leukemia

The most common, expected, and reversible treatment-emergent adverse event associated with the agent was cytokine release syndrome.

Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news